Annual EBITDA:
-$336.07M-$114.56M(-51.72%)Summary
- As of today, CRNX annual EBITDA is -$336.07 million, with the most recent change of -$114.56 million (-51.72%) on December 31, 2024.
- During the last 3 years, CRNX annual EBITDA has fallen by -$229.29 million (-214.73%).
- CRNX annual EBITDA is now -5580.68% below its all-time high of -$5.92 million, reached on December 31, 2016.
Performance
CRNX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$141.57M-$13.42M(-10.47%)Summary
- As of today, CRNX quarterly EBITDA is -$141.57 million, with the most recent change of -$13.42 million (-10.47%) on September 30, 2025.
- Over the past year, CRNX quarterly EBITDA has dropped by -$54.55 million (-62.68%).
- CRNX quarterly EBITDA is now -5289.19% below its all-time high of -$2.63 million, reached on March 31, 2017.
Performance
CRNX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$474.16M-$54.55M(-13.00%)Summary
- As of today, CRNX TTM EBITDA is -$474.16 million, with the most recent change of -$54.55 million (-13.00%) on September 30, 2025.
- Over the past year, CRNX TTM EBITDA has dropped by -$168.62 million (-55.19%).
- CRNX TTM EBITDA is now -17949.64% below its all-time high of -$2.63 million, reached on March 31, 2017.
Performance
CRNX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CRNX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -51.7% | -62.7% | -55.2% |
| 3Y3 Years | -214.7% | -225.0% | -208.1% |
| 5Y5 Years | -534.8% | -680.6% | -601.9% |
CRNX EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -214.7% | at low | -225.0% | at low | -208.1% | at low |
| 5Y | 5-Year | -534.8% | at low | -680.6% | at low | -601.9% | at low |
| All-Time | All-Time | -5580.7% | at low | -5289.2% | at low | >-9999.0% | at low |
CRNX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$141.57M(-10.5%) | -$474.16M(-13.0%) |
| Jun 2025 | - | -$128.15M(-16.0%) | -$419.62M(-12.2%) |
| Mar 2025 | - | -$110.48M(-17.6%) | -$373.89M(-10.9%) |
| Dec 2024 | -$336.07M(-51.7%) | -$93.96M(-8.0%) | -$337.11M(-10.3%) |
| Sep 2024 | - | -$87.03M(-5.6%) | -$305.55M(-10.1%) |
| Jun 2024 | - | -$82.43M(-11.9%) | -$277.57M(-11.6%) |
| Mar 2024 | - | -$73.69M(-18.1%) | -$248.73M(-10.4%) |
| Dec 2023 | -$221.51M(-32.7%) | -$62.40M(-5.7%) | -$225.29M(-7.2%) |
| Sep 2023 | - | -$59.05M(-10.2%) | -$210.06M(-8.0%) |
| Jun 2023 | - | -$53.59M(-6.6%) | -$194.57M(-5.7%) |
| Mar 2023 | - | -$50.26M(-6.6%) | -$184.16M(-8.0%) |
| Dec 2022 | -$166.90M(-56.3%) | -$47.17M(-8.3%) | -$170.52M(-10.8%) |
| Sep 2022 | - | -$43.56M(-0.9%) | -$153.91M(-11.7%) |
| Jun 2022 | - | -$43.17M(-17.9%) | -$137.84M(-14.4%) |
| Mar 2022 | - | -$36.62M(-19.8%) | -$120.45M(-13.2%) |
| Dec 2021 | -$106.78M | -$30.56M(-11.2%) | -$106.44M(-9.3%) |
| Sep 2021 | - | -$27.49M(-6.6%) | -$97.37M(-10.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$25.78M(-14.0%) | -$88.02M(-11.6%) |
| Mar 2021 | - | -$22.61M(-5.2%) | -$78.86M(-6.9%) |
| Dec 2020 | -$74.00M(-39.8%) | -$21.49M(-18.5%) | -$73.80M(-9.2%) |
| Sep 2020 | - | -$18.14M(-9.1%) | -$67.55M(-4.1%) |
| Jun 2020 | - | -$16.62M(+5.3%) | -$64.92M(-5.7%) |
| Mar 2020 | - | -$17.55M(-15.1%) | -$61.42M(-13.7%) |
| Dec 2019 | -$52.95M(-87.5%) | -$15.25M(+1.7%) | -$54.02M(-10.7%) |
| Sep 2019 | - | -$15.51M(-18.2%) | -$48.78M(-16.8%) |
| Jun 2019 | - | -$13.12M(-29.1%) | -$41.76M(-19.6%) |
| Mar 2019 | - | -$10.16M(-1.5%) | -$34.91M(-13.8%) |
| Dec 2018 | -$28.24M(-213.8%) | -$10.00M(-18.0%) | -$30.67M(-48.4%) |
| Sep 2018 | - | -$8.48M(-35.4%) | -$20.66M(-36.2%) |
| Jun 2018 | - | -$6.26M(-5.8%) | -$15.17M(-70.3%) |
| Mar 2018 | - | -$5.92M(-98.3%) | -$8.91M(-58.7%) |
| Dec 2017 | -$9.00M(-52.1%) | - | - |
| Sep 2017 | - | -$2.99M(-13.7%) | -$5.61M(-113.7%) |
| Mar 2017 | - | -$2.63M | -$2.63M |
| Dec 2016 | -$5.92M | - | - |
FAQ
- What is Crinetics Pharmaceuticals, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Crinetics Pharmaceuticals, Inc.?
- What is Crinetics Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Crinetics Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Crinetics Pharmaceuticals, Inc.?
- What is Crinetics Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Crinetics Pharmaceuticals, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Crinetics Pharmaceuticals, Inc.?
- What is Crinetics Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Crinetics Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of CRNX is -$336.07M
What is the all-time high annual EBITDA for Crinetics Pharmaceuticals, Inc.?
Crinetics Pharmaceuticals, Inc. all-time high annual EBITDA is -$5.92M
What is Crinetics Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, CRNX annual EBITDA has changed by -$114.56M (-51.72%)
What is Crinetics Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of CRNX is -$141.57M
What is the all-time high quarterly EBITDA for Crinetics Pharmaceuticals, Inc.?
Crinetics Pharmaceuticals, Inc. all-time high quarterly EBITDA is -$2.63M
What is Crinetics Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, CRNX quarterly EBITDA has changed by -$54.55M (-62.68%)
What is Crinetics Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of CRNX is -$474.16M
What is the all-time high TTM EBITDA for Crinetics Pharmaceuticals, Inc.?
Crinetics Pharmaceuticals, Inc. all-time high TTM EBITDA is -$2.63M
What is Crinetics Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, CRNX TTM EBITDA has changed by -$168.62M (-55.19%)